2 ms·
The NIH has claims on the 2P mutation in the spike that appears to make it better. Cellscript holds the N1mPsi patent (may not be essential, watch for CureVac p
by DrAwdeOccarim 5y ago
The NIH has claims on the 2P mutation in the spike that appears to make it better. Cellscript holds the N1mPsi patent (may not be essential, watch for CureVac p3 read out soon). The ionizable lipids currently have composition of matter coverage for a few companies, which is probably the crux of the discussion. Everything else is confidential know-how, which is already scaling as fast. I'm not sure exactly what this gets anyone...